Ulf Samuelsson1, Karin Åkesson2,3, Anette Peterson4, Ragnar Hanas5,6, Lena Hanberger7. 1. Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 2. Department of Pediatrics, County Hospital Ryhov, Jönköping, Sweden. 3. The Jönköping Academy for Improvement of Health and Welfare, Jönköping University, Jönköping, Sweden. 4. School of Health and Science, The Jönköping Academy for Improvement of Health and Welfare and Jönköping County Council, Jönköping University, Jönköping, Sweden. 5. Department of Pediatrics, NU Hospital Group, Uddevalla Hospital, Uddevalla, Sweden. 6. The Sahlgrenska Academy, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden. 7. Division of Nursing, Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Abstract
BACKGROUND: To prospectively investigate if the grand mean HbA1c and the differences in mean HbA1c between centers in Sweden could be reduced, thereby improving care delivered by pediatric diabetes teams. METHODS: We used an 18-month quality improvement collaborative (QIC) together with the Swedish pediatric diabetes quality registry (SWEDIABKIDS). The first program (IQ-1), started in April 2011 and the second (IQ-2) in April 2012; together they encompassed 70% of Swedish children and adolescents with diabetes. RESULTS: The proportion of patients in IQ-1 with a mean HbA1c <7.4% (57 mmol/mol) increased from 26.4% before start to 35.9% at 36 months (P < .001), and from 30.2% to 37.2% (P < .001) for IQ-2. Mean HbA1c decreased in both participating and non-participating (NP) centers in Sweden, thereby indicating an improvement by a spatial spill over effect in NP centers. The grand mean HbA1c decreased by 0.45% (4.9 mmol/mol) during 36 months; at the end of 2014 it was 7.43% (57.7 mmol/mol) (P < .001). A linear regression model with the difference in HbA1c before start and second follow-up as dependent variable showed that QIC participation significantly decreased mean HbA1c both for IQ-1 and IQ-2. The proportion of patients with high HbA1c values (>8.7%, 72 mmol/mol) decreased significantly in both QICs, while it increased in the NP group. CONCLUSIONS: The grand mean HbA1c has decreased significantly in Sweden from 2010 to 2014, and QICs have contributed significantly to this decrease. There seems to be a spatial spill-over effect in NP centers.
BACKGROUND: To prospectively investigate if the grand mean HbA1c and the differences in mean HbA1c between centers in Sweden could be reduced, thereby improving care delivered by pediatric diabetes teams. METHODS: We used an 18-month quality improvement collaborative (QIC) together with the Swedish pediatric diabetes quality registry (SWEDIABKIDS). The first program (IQ-1), started in April 2011 and the second (IQ-2) in April 2012; together they encompassed 70% of Swedish children and adolescents with diabetes. RESULTS: The proportion of patients in IQ-1 with a mean HbA1c <7.4% (57 mmol/mol) increased from 26.4% before start to 35.9% at 36 months (P < .001), and from 30.2% to 37.2% (P < .001) for IQ-2. Mean HbA1c decreased in both participating and non-participating (NP) centers in Sweden, thereby indicating an improvement by a spatial spill over effect in NP centers. The grand mean HbA1c decreased by 0.45% (4.9 mmol/mol) during 36 months; at the end of 2014 it was 7.43% (57.7 mmol/mol) (P < .001). A linear regression model with the difference in HbA1c before start and second follow-up as dependent variable showed that QIC participation significantly decreased mean HbA1c both for IQ-1 and IQ-2. The proportion of patients with high HbA1c values (>8.7%, 72 mmol/mol) decreased significantly in both QICs, while it increased in the NP group. CONCLUSIONS: The grand mean HbA1c has decreased significantly in Sweden from 2010 to 2014, and QICs have contributed significantly to this decrease. There seems to be a spatial spill-over effect in NP centers.
Authors: Dimitrios Charalampopoulos; Julia M Hermann; Jannet Svensson; Torild Skrivarhaug; David M Maahs; Karin Akesson; Justin T Warner; Reinhard W Holl; Niels H Birkebæk; Ann K Drivvoll; Kellee M Miller; Ann-Marie Svensson; Terence Stephenson; Sabine E Hofer; Siri Fredheim; Siv J Kummernes; Nicole Foster; Lena Hanberger; Rakesh Amin; Birgit Rami-Merhar; Anders Johansen; Knut Dahl-Jørgensen; Mark Clements; Ragnar Hanas Journal: Diabetes Care Date: 2018-04-12 Impact factor: 19.112
Authors: Rayzel Shulman; Ian Zenlea; Baiju R Shah; Cheril Clarson; Jennifer Harrington; Alanna Landry; Zubin Punthakee; Mark R Palmert; Geetha Mukerji; Peter C Austin; Janet Parsons; Noah Ivers Journal: BMC Health Serv Res Date: 2019-11-25 Impact factor: 2.655
Authors: Maria J Redondo; Ingrid Libman; David M Maahs; Sarah K Lyons; Mindy Saraco; Jane Reusch; Henry Rodriguez; Linda A DiMeglio Journal: Diabetes Care Date: 2021-01-11 Impact factor: 19.112
Authors: Shengxin Liu; Marica Leone; Jonas F Ludvigsson; Paul Lichtenstein; Brian D'Onofrio; Ann-Marie Svensson; Soffia Gudbjörnsdottir; Sarah E Bergen; Henrik Larsson; Ralf Kuja-Halkola; Agnieszka Butwicka Journal: Diabetes Care Date: 2022-09-01 Impact factor: 17.152
Authors: Priya Prahalad; Dessi P Zaharieva; Ananta Addala; Christin New; David Scheinker; Manisha Desai; Korey K Hood; David M Maahs Journal: Front Endocrinol (Lausanne) Date: 2020-07-09 Impact factor: 5.555
Authors: B Rathsman; J Haas; M Persson; J Ludvigsson; A-M Svensson; M Lind; M Andersson Franko; T Nyström Journal: J Intern Med Date: 2020-12-27 Impact factor: 8.989